FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751497703> ?p ?o ?g. }

• W2751497703 endingPage "355" @default.
• W2751497703 startingPage "347" @default.
• W2751497703 abstract "Background and Purpose Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis (IVT) or endovascular treatment (EVT). Methods This was a single-center explorative analysis using data from the Novel-Oral-Anticoagulants-in-Stroke-Patients-registry (clinicaltrials.gov:NCT02353585) including acute stroke patients taking rivaroxaban (September 2012 to November 2016). The SOP included recommendation, consideration, and avoidance of IVT if rivaroxaban plasma levels were <20 ng/mL, 20‒100 ng/mL, and >100 ng/mL, respectively, measured with a calibrated anti-factor Xa assay. Patients with intracranial artery occlusion were recommended IVT+EVT or EVT alone if plasma levels were ≤100 ng/mL or >100 ng/mL, respectively. We evaluated the frequency of IVT/EVT, door-to-needle-time (DNT), and symptomatic intracranial or major extracranial hemorrhage. Results Among 114 acute stroke patients taking rivaroxaban, 68 were otherwise eligible for IVT/EVT of whom 63 had plasma levels measured (median age 81 years, median baseline National Institutes of Health Stroke Scale 6). Median rivaroxaban plasma level was 96 ng/mL (inter quartile range [IQR] 18‒259 ng/mL) and time since last intake 11 hours (IQR 4.5‒18.5 hours). Twenty-two patients (35%) received IVT/EVT (IVT n=15, IVT+EVT n=3, EVT n=4) based on SOP. Median DNT was 37 (IQR 30‒60) minutes. None of the 31 patients with plasma levels >100 ng/mL received IVT. Among 14 patients with plasma levels ≤100 ng/mL, the main reason to withhold IVT was minor stroke (n=10). No symptomatic intracranial or major extracranial bleeding occurred after treatment. Conclusions Determination of rivaroxaban plasma levels enabled IVT or EVT in one-third of patients taking rivaroxaban who would otherwise be ineligible for acute treatment. The absence of major bleeding in our pilot series justifies future studies of this approach. Keywords: Rivaroxaban; Stroke; Plasma levels; Thrombolysis" @default.
• W2751497703 created "2017-09-15" @default.
• W2751497703 creator A5001755897 @default.
• W2751497703 creator A5007119825 @default.
• W2751497703 creator A5010194490 @default.
• W2751497703 creator A5011568032 @default.
• W2751497703 creator A5045084521 @default.
• W2751497703 creator A5053169486 @default.
• W2751497703 creator A5053562303 @default.
• W2751497703 creator A5055958311 @default.
• W2751497703 creator A5056255583 @default.
• W2751497703 creator A5064472070 @default.
• W2751497703 creator A5065590767 @default.
• W2751497703 creator A5068795011 @default.
• W2751497703 creator A5069437629 @default.
• W2751497703 creator A5070810264 @default.
• W2751497703 creator A5075785208 @default.
• W2751497703 creator A5076072571 @default.
• W2751497703 creator A5078877581 @default.
• W2751497703 creator A5082162689 @default.
• W2751497703 creator A5087679522 @default.
• W2751497703 creator A5088394837 @default.
• W2751497703 date "2017-09-30" @default.
• W2751497703 modified "2023-10-14" @default.
• W2751497703 title "Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice" @default.
• W2751497703 cites W1870017071 @default.
• W2751497703 cites W1946167122 @default.
• W2751497703 cites W1982206405 @default.
• W2751497703 cites W1996802760 @default.
• W2751497703 cites W2001598988 @default.
• W2751497703 cites W2005273495 @default.
• W2751497703 cites W2023917690 @default.
• W2751497703 cites W2027123157 @default.
• W2751497703 cites W2035435004 @default.
• W2751497703 cites W2041600305 @default.
• W2751497703 cites W2046188252 @default.
• W2751497703 cites W2060578439 @default.
• W2751497703 cites W2083713858 @default.
• W2751497703 cites W2083816104 @default.
• W2751497703 cites W2097854437 @default.
• W2751497703 cites W2098032054 @default.
• W2751497703 cites W2102447759 @default.
• W2751497703 cites W2106668399 @default.
• W2751497703 cites W2106783243 @default.
• W2751497703 cites W2109783545 @default.
• W2751497703 cites W2127272421 @default.
• W2751497703 cites W2148656951 @default.
• W2751497703 cites W2153664287 @default.
• W2751497703 cites W2155965977 @default.
• W2751497703 cites W2159233098 @default.
• W2751497703 cites W2159577033 @default.
• W2751497703 cites W2164363187 @default.
• W2751497703 cites W2164763924 @default.
• W2751497703 cites W2168419094 @default.
• W2751497703 cites W2170488085 @default.
• W2751497703 cites W2171165037 @default.
• W2751497703 cites W2203834727 @default.
• W2751497703 cites W2527589302 @default.
• W2751497703 cites W2557371738 @default.
• W2751497703 cites W2607031541 @default.
• W2751497703 cites W2612024030 @default.
• W2751497703 cites W2885288119 @default.
• W2751497703 cites W4240994847 @default.
• W2751497703 doi "https://doi.org/10.5853/jos.2017.00395" @default.
• W2751497703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5647628" @default.
• W2751497703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28877563" @default.
• W2751497703 hasPublicationYear "2017" @default.
• W2751497703 type Work @default.
• W2751497703 sameAs 2751497703 @default.
• W2751497703 citedByCount "45" @default.
• W2751497703 countsByYear W27514977032017 @default.
• W2751497703 countsByYear W27514977032018 @default.
• W2751497703 countsByYear W27514977032019 @default.
• W2751497703 countsByYear W27514977032020 @default.
• W2751497703 countsByYear W27514977032021 @default.
• W2751497703 countsByYear W27514977032022 @default.
• W2751497703 countsByYear W27514977032023 @default.
• W2751497703 crossrefType "journal-article" @default.
• W2751497703 hasAuthorship W2751497703A5001755897 @default.
• W2751497703 hasAuthorship W2751497703A5007119825 @default.
• W2751497703 hasAuthorship W2751497703A5010194490 @default.
• W2751497703 hasAuthorship W2751497703A5011568032 @default.
• W2751497703 hasAuthorship W2751497703A5045084521 @default.
• W2751497703 hasAuthorship W2751497703A5053169486 @default.
• W2751497703 hasAuthorship W2751497703A5053562303 @default.
• W2751497703 hasAuthorship W2751497703A5055958311 @default.
• W2751497703 hasAuthorship W2751497703A5056255583 @default.
• W2751497703 hasAuthorship W2751497703A5064472070 @default.
• W2751497703 hasAuthorship W2751497703A5065590767 @default.
• W2751497703 hasAuthorship W2751497703A5068795011 @default.
• W2751497703 hasAuthorship W2751497703A5069437629 @default.
• W2751497703 hasAuthorship W2751497703A5070810264 @default.
• W2751497703 hasAuthorship W2751497703A5075785208 @default.
• W2751497703 hasAuthorship W2751497703A5076072571 @default.
• W2751497703 hasAuthorship W2751497703A5078877581 @default.
• W2751497703 hasAuthorship W2751497703A5082162689 @default.
• W2751497703 hasAuthorship W2751497703A5087679522 @default.
• W2751497703 hasAuthorship W2751497703A5088394837 @default.

• next